NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025
Buyers
Value
£24
Suppliers
- Biogen
- Amgen Ltd
- Sobi (Swedish Orphan Biovitrum Ltd)
- Zentiva Pharma UK Ltd
- Fresenius Kabi Limited
- Sandoz Ltd
- Thornton and Ross Ltd
- Roche Products Ltd
- ACCORD-UK LTD
- GLAXOSMITHKLINE UK LIMITED
- Samsung Bioepis UK Ltd
- Pfizer Ltd
- Janssen-Cilag Ltd
- Celltrion Healthcare United Kingdom Limited
- ABBVIE LTD
- Takeda UK Ltd
- Organon Pharmaceuticals UK Ltd
- Alexion Pharmaceuticals
- Orifarm UK
- CuraTeQ Biologics s.r.o.
- Dr.Reddy's Laboratories (UK) Limited
Classifications
- Pharmaceutical products
Tags
- award
- contract
Published
1 day ago
Description
NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025<br/>CM/PHR/24/5680/01 - Tranche B for North of England and Midlands & East. Period of Framework Agreement: 01 September 2025 to 31 August 2027 <br/>CM/PHR/24/5680/02 - Eculizumab and Ravulizumab for London & SOFE. Period of Framework Agreement: 01 September 2025 to 31 August 2026
Similar Contracts
AI Bid Assistant
Our AI-powered tool to help you create winning bids is coming soon!
Timeline complete
Complete